Scientific Expertise to Help Solve Technical Roadblocks
During development of a new apheresis device, a client detected higher levels of complement activation than historical experience and were concerned that device development would be slowed down. A BioPhia SME was able to review the data and recommend subsequent experiments that when coupled with a review of the literature could explain the activation and keep the development on track.
A client was developing a new apheresis device. Monitoring complement activation after blood exposure, they found higher levels compared to historical experience. The client was concerned this would slow development of the device.
BioPhia was engaged to provide SME review of the in vitro complement activation data and provide insight into possible reasons for the apparent levels and suggest the next steps.
An initial meeting produced a document that explained the data in the context of extracorporeal blood contact and outlined a set of follow-up experiments to resolve any issues.
A white paper was generated that included background on complement activation, the original data and results from follow-up work. This was included as an addendum to an internal report on the device development project.